全文获取类型
收费全文 | 27469篇 |
免费 | 1361篇 |
国内免费 | 189篇 |
专业分类
耳鼻咽喉 | 290篇 |
儿科学 | 589篇 |
妇产科学 | 483篇 |
基础医学 | 4163篇 |
口腔科学 | 423篇 |
临床医学 | 2315篇 |
内科学 | 5155篇 |
皮肤病学 | 896篇 |
神经病学 | 3304篇 |
特种医学 | 1375篇 |
外国民族医学 | 5篇 |
外科学 | 3516篇 |
综合类 | 186篇 |
一般理论 | 6篇 |
预防医学 | 1199篇 |
眼科学 | 682篇 |
药学 | 2153篇 |
中国医学 | 29篇 |
肿瘤学 | 2250篇 |
出版年
2023年 | 126篇 |
2022年 | 221篇 |
2021年 | 358篇 |
2020年 | 291篇 |
2019年 | 351篇 |
2018年 | 464篇 |
2017年 | 363篇 |
2016年 | 524篇 |
2015年 | 580篇 |
2014年 | 800篇 |
2013年 | 1008篇 |
2012年 | 1532篇 |
2011年 | 1645篇 |
2010年 | 925篇 |
2009年 | 947篇 |
2008年 | 1708篇 |
2007年 | 1705篇 |
2006年 | 1800篇 |
2005年 | 1839篇 |
2004年 | 1665篇 |
2003年 | 1717篇 |
2002年 | 1586篇 |
2001年 | 478篇 |
2000年 | 414篇 |
1999年 | 464篇 |
1998年 | 404篇 |
1997年 | 334篇 |
1996年 | 267篇 |
1995年 | 207篇 |
1994年 | 243篇 |
1993年 | 182篇 |
1992年 | 204篇 |
1991年 | 208篇 |
1990年 | 193篇 |
1989年 | 173篇 |
1988年 | 188篇 |
1987年 | 145篇 |
1986年 | 137篇 |
1985年 | 131篇 |
1984年 | 132篇 |
1983年 | 117篇 |
1982年 | 113篇 |
1981年 | 123篇 |
1980年 | 98篇 |
1979年 | 115篇 |
1978年 | 77篇 |
1977年 | 87篇 |
1976年 | 83篇 |
1974年 | 99篇 |
1973年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Tanja Bauer Matthias Günther Ulrich Bienzle Ruth Neuhaus Wolfgang Jilg 《Liver transplantation》2007,13(3):434-442
After liver transplantation for hepatitis-B-related diseases, patients currently receive lifelong treatment with hepatitis B immunoglobulin to prevent endogenous reinfection with hepatitis B virus (HBV). Active immunization with hepatitis B vaccine would be a preferable alternative; however, most attempts to immunize these patients with standard vaccine have failed. A recent study with a new adjuvanted hepatitis B vaccine was exceptionally successful, leading to a high-titered long-lasting antibody response in 80% of all vaccinees. To identify the immunological mechanisms behind these unexpected results, the successfully vaccinated participants were tested for hepatitis B surface antigen (HBsAg)-specific T and B cells, and their cellular responses to revaccination with conventional vaccine were studied. HBsAg-specific CD4(+) T lymphocytes could be detected in 13 of 16 patients after immunization with the new vaccine. Unexpectedly, these T cells produced almost exclusively interleukin (IL)-10 and had a CD4(+)/CD25(+) phenotype. They were functionally active, suppressing cytokine secretion in HBsAg-specific (Th1) cells, thus representing antigen-specific regulatory T cells (T(Reg)). Following a booster dose with conventional vaccine 22-31 months after completion of the initial vaccination series, the T-cell pattern in the revaccinated individuals changed substantially: 7 days after revaccination 9 of 11 individuals showed a switch to a Th1-type immune response with HBsAg-specific T cells secreting IL-2, interferon gamma and tumor necrosis factor alpha as observed in healthy controls. Four weeks after the booster, 4 patients still showed a Th1-type cytokine pattern, whereas in 5 patients only IL-10-secreting cells were detectable. After 1 year, in 3 of 4 revaccinated individuals only IL-10-secreting cells could be found, whereas the specific T cells of the fourth patient still showed a Th1-type of response. HBsAg-specific T(Reg) cells could be demonstrated in HBV-positive liver transplant recipients successfully immunized with a new adjuvanted vaccine. Revaccination led to immediate disappearance of the these cells and the appearance of HBsAg-specific T cells with a Th1-type cytokine profile, which in most cases were replaced by the IL-10-secreting regulatory cells during the following months. The specific induction of T(Reg) cells could contribute to the poor response of liver transplant recipients to conventional vaccine. In conclusion,, for successful vaccination of these patients, a vaccine with a strong inhibitory effect on T(Reg) cells would be desirable. 相似文献
32.
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. 总被引:1,自引:0,他引:1
Jens P Bankstahl Claudia Kuntner Aiman Abrahim Rudolf Karch Johann Stanek Thomas Wanek Wolfgang Wadsak Kurt Kletter Markus Müller Wolfgang L?scher Oliver Langer 《Journal of nuclear medicine》2008,49(8):1328-1335
The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in high concentrations at the blood-brain barrier (BBB) and is believed to be implicated in resistance to central nervous system drugs. We used small-animal PET and (R)-11C-verapamil together with tariquidar, a new-generation P-gp modulator, to study the functional activity of P-gp at the BBB of rats. To enable a comparison with human PET data, we performed kinetic modeling to estimate the rate constants of radiotracer transport across the rat BBB. METHODS: A group of 7 Wistar Unilever rats underwent paired (R)-11C-verapamil PET scans at an interval of 3 h: 1 baseline scan and 1 scan after intravenous injection of tariquidar (15 mg/kg, n = 5) or vehicle (n = 2). RESULTS: After tariquidar administration, the distribution volume (DV) of (R)-11C-verapamil was 12-fold higher than baseline (3.68 +/- 0.81 vs. 0.30 +/- 0.08; P = 0.0007, paired t test), whereas the DVs were essentially the same when only vehicle was administered. The increase in DV could be attributed mainly to an increased influx rate constant (K1) of (R)-11C-verapamil into the brain, which was about 8-fold higher after tariquidar. A dose-response assessment with tariquidar provided an estimated half-maximum effect dose of 8.4 +/- 9.5 mg/kg. CONCLUSION: Our data demonstrate that (R)-11C-verapamil PET combined with tariquidar administration is a promising approach to measure P-gp function at the BBB. 相似文献
33.
Sandra Urdaneta Hartmann Brian Wigdahl Elizabeth B Neely Cheston M Berlin Cara-Lynne Schengrund Hung-Mo Lin Mary K Howett 《Journal of human lactation》2006,22(1):61-74
Reduction of transmission of human immunodeficiency virus type 1 (HIV-1) through human milk is needed. Alkyl sulfates such as sodium dodecyl sulfate (SDS) are microbicidal against HIV-1 at low concentrations, have little to no toxicity, and are inexpensive. The authors have reported that treatment of HIV-1-infected human milk with < or = 1% (10 mg/mL) SDS for 10 minutes inactivates cell-free and cell-associated virus. The SDS can be removed with a commercially available resin after treatment without recovery of viral infectivity. In this article, the authors report results of selective biochemical analyses (ie, protein, immunoglobulins, lipids, cells, and electrolytes) of human milk subjected to SDS treatment and removal. The SDS treatment or removal had no significant effects on the milk components studied. Therefore, the use of alkyl sulfate microbicides to treat milk from HIV-1-positive women may be a simple, practical, and nutritionally sound way to prevent or reduce transmission of HIV-1 while still feeding with mother's own milk. 相似文献
34.
Burkhard H. A. von Rahden Brigitte Stigler Wolfgang Weiß Hubert J. Stein 《Journal of gastrointestinal surgery》2007,11(7):945-947
Management of upper gastrointestinal bleeding because of erosion of vessels by esophageal cancer may be challenging. We present
herein the angiographic images of a 49-year-old patient who was admitted with massive bleeding from a tumor-eroded inferior
thyroid artery. Attempts to control the bleeding by means of flexible endoscopy and insertion of a Sengstaken–Blakemore tube
had failed. The diagnosis was impressively demonstrated by multislice computed tomography with intravenous contrast in the
arterial phase and multiplanar reconstructions (computed tomography angiography) and by digital subtraction angiography. The
bleeding was successfully treated with superselective catheterization and coiling of the eroded vessel. 相似文献
35.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients 总被引:1,自引:0,他引:1
A. Åsberg A. Humar H. Rollag A. G. Jardine H. Mouas M. D. Pescovitz D. Sgarabotto M. Tuncer I. L. Noronha A. Hartmann 《American journal of transplantation》2007,7(9):2106-2113
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study. 相似文献
36.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung† K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K. D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(4):320-332
The first part of this serial paper dealt with the medical criteria used in evaluation of the clinical picture caused by physical stress and the evaluation of other candidate causes and was published in issue no. 3/2005 (pp. 711–752) of Trauma and Berufskrankheit. This follow-up paper (II) presents criteria to be used in the evaluation of whether it is necessary to give up the occupations putting the spine at risk and in estimation of the degree of disability. 相似文献
37.
38.
Gregory J. Pomper Rita A. Joseph Erica L. Hartmann Michael S. Rohr Patricia L. Adams Robert J. Stratta 《American journal of transplantation》2005,5(10):2586-2589
Massive immune hemolysis due to passenger lymphocyte-derived anti-D has not been reported in renal transplantation. A 50-year-old (B-positive) male received a dual deceased-donor kidney transplant (B-negative) for diabetic renal failure. Two weeks post-transplant, the patient developed severe hemolytic anemia. The donor anti-D titer was 1:8. The recipient anti-D titer (zero pre-transplant) increased from 1:4 to 1:16 over 4 days. Rapid hemolysis caused severe anemia, minimum Hb = 4.2 g/dL, while selectively lysing the patient's autologous red cells during this time. The hemolytic anemia did not impair the allografts and subsided without monoclonal B-cell pharmacotherapy or apheresis. The anti-D titer decreased to barely detectable levels at four months and had cleared when checked 2 years post-transplant. Transfusion support subsided after two months. If complications of anemia can be avoided, the deleterious effects of hemolysis may be well tolerated by renal allografts using antigen negative transfusion alone. 相似文献
39.
40.
Sibylle von Vietinghoff Wolfgang Schneider Friedrich C Luft Ralph Kettritz 《Nephrology, dialysis, transplantation》2006,21(11):3324-3326